Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome | Zendy

Sadettin Uslu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome

Author(s) -

Sadettin Uslu

Publication year - 2020

Publication title -

european journal of case reports in internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.125

H-Index - 1

ISSN - 2284-2594

DOI - 10.12890/2020_001731

Subject(s) - tocilizumab , medicine , cytokine release syndrome , covid-19 , interleukin 6 , cytokine , cytokine storm , disease , immunology , virology , infectious disease (medical specialty) , outbreak

Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin‐6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID‐19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research